Answer
With belumosudil mesilate (Rezurock) in patients with chronic graft-versus-host disease, asthenia (21.0%) and nausea (12.4%) meet the very common frequency category of at least 1 in 10 patients.
Sources for this answer
- REZUROCK 200 mg film-coated tablets.SANOFI · emc · SmPC §4.8 Undesirable effects · Version 8Document updated
Sources checked